-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sodium - glucose transporter (the SGLT2) 2 using an inhibitor is 2 type diabetes mellitus (T2DM) standard interventions the patient has good pleiotropic effects on lowering blood uric acid levels continued
.
However, so far, there are few studies on the association between the use of SGLT2 inhibitors and the incidence of gout
Sodium - glucose transporter (the SGLT2) 2 using an inhibitor is 2 type Diabetes diabetes (T2DM) standard interventions the patient has good pleiotropic effects on lowering blood uric acid levels continued
This retrospective cohort study analyzed 2016 Nian 5 Yue 1 to 2018 Nian 12 Yue 31 all occurred between Taiwan health authorities database date in T2DM patients
.
As a control, patients using dipeptidyl peptidase 4 ( DPP4 ) inhibitors were included
This retrospective cohort study analyzed 2016 Nian 5 Yue 1 to 2018 Nian 12 Yue 31 all occurred between Taiwan health authorities database date in T2DM patients
A total of 231208 Ming 2 diabetes patients with type into the crowd, 113,812 people ( 49.
The incidence of gout in type 2 diabetic patients receiving dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors
The incidence of gout in type 2 diabetic patients receiving dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitorsWhen using ICD-9-CM or ICD-10-CM codes and gout-related drugs to determine the diagnosis of gout , the sensitivity analysis also showed that the incidence of gout with SGLT2 inhibitors was significantly reduced by 15% ( HR , 0.
85 ; 95%) CI , 0.
74-0.
97 )
.
Subgroup analysis showed that the benefits of SGLT2 inhibitors in reducing the risk of gout in T2DM patients did not differ among the subgroups
When using ICD-9-CM or ICD-10-CM codes and gout-related drugs to determine the diagnosis of gout , sensitivity analysis also showed that the incidence of gout using diagnostic SGLT2 inhibitors was significantly reduced by 15% ( HR , 0.
Incidence and risk of gout in patients with type 2 diabetes with DPP4 and SGLT2 inhibitors
Incidence and risk of gout in patients with type 2 diabetes with DPP4 and SGLT2 inhibitorsThe results of this study showed that patients with T2DM who received SGLT2 inhibitors had a lower risk of gout compared with patients with T2DM who received DPP4 inhibitors
.
.
Compared with T2DM patients who received DPP4 inhibitors, T2DM patients who received SGLT2 inhibitors had a lower risk of gout
Chung M, Hung P, Hsiao P, et al.
Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
JAMA Netw Open.
JAMA2021;4(11):e2135353.
doi:10.
1001 /jamanetworkopen.
2021.
35353 doi:10.
1001/jamanetworkopen.
2021.
35353 leave a message here